Systemic vasculitis encompasses a group of conditions characterised by inflammation of blood vessel walls, leading to ischaemia and organ damage depending on which vessels are affected. ANCA-associated vasculitis (AAV) -- granulomatosis with polyangiitis (GPA, formerly Wegener), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss) -- are the most common small-vessel vasculitides in adults. Walking cane need in systemic vasculitis depends on which organ systems are damaged.
Vasculitis Features Affecting Gait and Mobility
- Peripheral neuropathy (mononeuritis multiplex): characteristic of ANCA vasculitis (especially MPA and EGPA). Multiple individual nerves are affected asymmetrically, causing focal weakness and sensory loss. Foot drop, peroneal nerve involvement, and sensory ataxia can all result.
- Renal involvement (RPGN): rapidly progressive glomerulonephritis causes fatigue and anaemia, limiting walking tolerance
- Pulmonary involvement: pulmonary haemorrhage (GPA, MPA), or asthma/eosinophilic pneumonia (EGPA) limits exertional capacity
- Ischaemic complications: mesenteric ischaemia, cerebral vasculitis (rare), or peripheral limb ischaemia may cause acute functional deficits
- Treatment toxicity: high-dose corticosteroids cause proximal myopathy, osteoporosis fractures, and avascular necrosis -- all cane indications in their own right
ANCA Vasculitis and Walking Cane: By Manifestation
| AAV Manifestation | Gait Problem | Cane Role |
|---|---|---|
| Mononeuritis multiplex (foot drop) | Foot drop; steppage gait; ankle instability | Contralateral cane; ankle-foot orthosis (AFO) for drop foot |
| Peripheral sensory neuropathy | Proprioceptive loss; sensory ataxia; unstable gait | Cane for balance; increases ground contact proprioceptive input via shaft |
| Steroid myopathy | Proximal weakness; Trendelenburg gait; stair difficulty | Contralateral cane; trekking poles for bilateral weakness |
| Steroid-induced AVN | Hip or knee pain; antalgic gait | Contralateral cane; same protocol as primary AVN |
| Fatigue / anaemia | Reduced walking endurance | Cane reduces metabolic cost per step |
Remission and Cane Use in AAV
AAV is treated with immunosuppression (rituximab or cyclophosphamide for induction; azathioprine or rituximab for maintenance). With effective treatment and disease remission, many AAV manifestations improve or resolve. Peripheral neuropathy damage may be partial and permanent. Walking aid needs should be reassessed in remission -- some patients can discontinue the cane, others require it long-term if neuropathic deficit persists.
Explore DaiWalk walking canes. Related: Walking Cane for Behcet Disease | Walking Cane for Peroneal Nerve Palsy.
